Dr. Reddy’s Cleared by Delhi High Court to Export Semaglutide to Non-Patent Markets
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Dr Reddy’s Laboratories ( (RDY) ) is now available.
On March 9, 2026, the Division Bench of the Delhi High Court upheld an earlier Single-Judge order allowing Dr. Reddy’s Laboratories to manufacture the diabetes and obesity drug ingredient Semaglutide in India for export to countries where originator Novo Nordisk does not hold patents. The court refused to grant Novo Nordisk an interim injunction on Semaglutide-containing products, clarifying that the dispute remains sub judice and that, as of March 10, 2026, the company sees no material event requiring additional stock-exchange disclosure under Indian listing rules.
The most recent analyst rating on (RDY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based global pharmaceutical company focused on developing, manufacturing and marketing generics, active pharmaceutical ingredients and proprietary products across multiple therapeutic areas. Listed in India and on the New York Stock Exchange, it serves regulated and emerging markets, with a growing interest in complex and speciality medicines.
Average Trading Volume: 1,717,328
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.99B
For an in-depth examination of RDY stock, go to TipRanks’ Overview page.
